单联或双联抗血小板治疗改善动静脉移植物一年通畅率与总体生存
基于血管质量倡议(Vascular Quality Initiative)2011至2023年数据的回顾性研究,纳入49980例动静脉瘘(AVF)与12688例动静脉移植物(AVG)创建患者,比较无抗血小板(No APT)、单联抗血小板(SAPT)、双联抗血小板(DAPT)及阿司匹林联合抗凝(ASA+AC)的结局。SAPT改善AVG一年一期通畅率(48% vs 44%,P=0.03)并降低AVG死亡风险(HR 0.80,CI 0.64-1.00,P=0.05),DAPT进一步降低AVG一期通畅丧失风险(HR 0.64,CI 0.43-0.95,P=0.028);AVF与AVG患者中ASA+AC的生存均较差。
要点
- AVG患者SAPT较No APT改善一年一期通畅率(48% vs 44%,P=0.03)
- AVG患者SAPT降低死亡风险(HR 0.80,CI 0.64-1.00,P=0.05)
- AVF与AVG患者中ASA+AC的生存均较差
核心结论
- 通路创建后单联抗血小板治疗改善AVF与AVG的一期通畅率,并改善AVG患者的总体生存。
- DAPT可能进一步改善AVG患者的一期通畅率。
- 抗凝使用未见明确获益且可能有害,但更可能反映合并其他共病的高风险患者。
- 作者认为AVF创建后可考虑出院时给予SAPT,AVG创建后可考虑给予SAPT或DAPT。
研究设计与样本
- 回顾性研究,利用血管质量倡议(Vascular Quality Initiative)中2011至2023年接受AVF与AVG创建的患者。
- 将未使用抗血小板及抗凝的患者分为4组:无抗血小板(No APT)、单联抗血小板(SAPT)、双联抗血小板(DAPT)、阿司匹林联合抗凝(ASA+AC)。
- 采用单因素Kaplan-Meier(KM)与多因素回归分析评估总体生存、一期通畅率与二期通畅率。
- 共识别49980例AVF创建患者与12688例AVG创建患者。
主要发现
- AVG患者SAPT较No APT的一年一期通畅率在KM分析中改善(48% vs 44%,P=0.03)。
- AVF在KM分析中未见差异。
- 回归分析显示AVF一期通畅丧失风险降低(HR 0.90,CI 0.83-0.97,P=0.009)。
- AVG患者SAPT显示死亡风险降低(HR 0.80,CI 0.64-1.00,P=0.05)及一期通畅丧失风险降低(HR 0.80,CI 0.67-0.94,P=0.009)。
- DAPT亦显示AVG一期通畅丧失风险降低(HR 0.64,CI 0.43-0.95,P=0.028)。
临床怎么用
- 作者认为AVF创建后可考虑出院时给予SAPT。
- 作者认为AVG创建后可考虑给予SAPT或DAPT。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Following new dialysis access creation there is no consensus on the optimal use of anti-thrombotic therapy. Recent studies have suggested that single antiplatelet therapy may improve hospital mortality as well as patency. The aim of this study was to assess the role of different antiplatelet and anticoagulation therapies on outcomes following dialysis access creation. MATERIAL AND METHODS: A retrospective study was conducted utilizing patients from the Vascular Quality Initiative who underwent AV fistula (AVF) and AV graft (AVG) creation from 2011-2023. Patients who were antiplatelet and anticoagulation naive were separated into 4 cohorts: no antiplatelet (No APT), single antiplatelet (SAPT), dual antiplatelet (DAPT), and aspirin with anticoagulation (ASA + AC). Univariate Kaplan-Meier (KM) and multivariable regression analyses were conducted to assess overall survival, primary patency, and secondary patency. RESULTS: 49,980 patients with AVF creation and 12,688 patients with AVG creation were identified. AVG patients had improved 1-year primary patency with SAPT compared to No APT (48% vs. 44%, P = 0.03) on KM analysis. No difference on KM analysis was observed for AVF. Regression analysis showed decreased risk of loss of primary patency for AVF (HR 0.90, CI 0.83-0.97, P = 0.009). AVG with SAPT showed decreased risk of mortality (HR 0.80, CI 0.64-1.00, P = 0.05) and decreased risk of loss of primary patency (HR 0.80, CI 0.67-0.94, P = 0.009). DAPT also showed decreased risk of loss of primary patency for AVG (HR 0.64, CI 0.43-0.95, P = 0.028). Survival was worse for both AVF and AVG patients on ASA + AC on KM analysis. CONCLUSIONS: Single antiplatelet therapy following access creation improves primary patency for both AVF and AVG, as well as overall survival for those with AVG. DAPT may further improve primary patency in those with AVG. The use of anticoagulation shows no clear benefit and may be harmful, however is more likely to reflect higher risk patients with other co-morbidities. These results suggest that following an AVF one should consider discharging patients on SAPT, and following an AVG one should consider SAPT or DAPT.
引用
- Ebertz DP, Bose S, De Valle A, et al. Single or Dual Antiplatelet Therapy Improves One-Year Arteriovenous Graft Patency and Overall Survival. Ann Vasc Surg. 2024. PMID: 39615620. doi:10.1016/j.avsg.2024.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。